What Ферретаб комп. Treats: Main Uses and Benefits

Targeting Fatigue and Weakness Caused by Deficiency

This medication is primarily used to help with symptoms related to systemic imbalance, specifically chronic fatigue, generalized weakness, and low physical energy that result from a diagnosed lack of iron and folic acid. The therapeutic goal is to address these deficiencies. The therapeutic support contributes to easing the overall symptom load related to exhaustion.

The main clinical use is applied across domains where additional symptomatic support is needed, including iron deficiency anemia, folate deficiency, and conditions marked by increased physiological stress such as pregnancy or excessive blood loss. This therapy is relevant in contexts marked by increased discomfort or tension related to nutrient deficits.

“This therapy is relevant in contexts marked by increased discomfort or tension related to nutrient deficits.”

This foundational support is relevant for easing symptoms that create noticeable physiological strain. It helps improve day-to-day comfort and assists with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Fatigue and Weakness The medication is commonly used to help patients cope more steadily with symptom fluctuations during periods of increased physiological stress.

Regulatory References

1. NIH DailyMed drug label for Ferrous Fumarate/Folic Acid

The eligibility for using Ферретаб комп. is strictly defined by regulatory documents, primarily designating the medication for adults with a confirmed combined iron and folic acid deficiency. It is explicitly indicated for use in pregnant and lactating women due to the high nutritional demand during these periods, though use is often restricted until after the first 13 weeks of pregnancy.

Contraindications: Populations Who Must Not Use

Regulatory authorities state the medicine is strictly contraindicated in several patient populations:

• Patients with conditions resulting in iron overload (e.g., Haemochromatosis or Haemosiderosis).
• Individuals with untreated megaloblastic anaemia caused by a Vitamin B12 deficiency, as the folic acid component may complicate the diagnosis.
• Patients with active peptic ulcers or Inflammatory Bowel Disease (Regional Enteritis, Ulcerative Colitis).
• Those receiving concomitant parenteral (injected) iron therapy or repeated blood transfusions.

Age and Condition Restrictions

The medicine is generally not recommended for the pediatric population under 12 years of age. Use requires special caution for patients with haemoglobinopathies or a history of controlled peptic ulceration.

Interactions with other medicines and products

Interaction Scope

Category	Documented Interacting Substances
Medicinal product categories with documented interactions	Quinolone and Tetracycline antibiotics, Antacids, Bisphosphonates, Thyroid hormones, Levodopa and Methyldopa, Penicillamine, Mycophenolate Mofetil, Chloramphenicol, H2 -receptor antagonists, Proton Pump Inhibitors (PPIs), certain Antiepileptic drugs.
Specific interacting medicines (if explicitly listed)	Dimercaprol, Levothyroxine, Ciprofloxacin, Phenytoin, Sulfasalazine, Trimethoprim, Zinc Salts.
Mechanistic basis of interactions (only if stated in label)	Chelation leading to reduced absorption, pH-dependent absorption interference, Inhibition of Dihydrofolate Reductase (DHFR), Altered metabolism of Folic Acid, Delayed hematopoietic response.

Interaction Classifications (High-Level)

Classification	Regulatory Description
Interaction severity classification	Contraindicated ( Dimercaprol). Major/Clinically Significant (e.g., reduced efficacy of Levothyroxine and Quinolones), requiring timing rules.
Regulatory basis	Based on official prescribing information for Ferrous Fumarate and Folic Acid documented by government health authorities.

Resulting Interaction Structure

Official interaction statements:

• Dimercaprol is contraindicated for co-administration due to the risk of forming a toxic complex, which is explicitly noted in regulatory documentation.
• Co-administration with the iron component reduces the systemic exposure ( AUC, C max) of oral Tetracycline and Quinolone antibiotics, Thyroid hormones, Levodopa, Methyldopa, and Bisphosphonates.
• Absorption of the iron component is reduced by Antacids, Proton Pump Inhibitors, H2-receptor antagonists, Cholestyramine, Zinc Salts, and high intake of Calcium or Magnesium products.
• Timing separation requirements are mandatory for nearly all co-administered, absorption-sensitive medicines and Antacids to mitigate the risk of chelation or pH-dependent absorption failure.
• Sulfasalazine and Trimethoprim interfere with the absorption or utilization of Folic Acid, as documented in regulatory texts.

Connection to the overall interaction profile:

The official interaction profile is defined by chelation and altered absorption, which dictates that Ферретаб комп. must be physically separated in time from most co-administered agents to ensure adequate systemic exposure for all treatments. Folic Acid interactions primarily involve interference with its metabolism or absorption by specific antifolate agents. This regulatory structure focuses on procedural constraints required for safe co-administration.

Molecular Targets and Cofactor Role

Ферретаб комп. delivers ferrous fumarate, an iron source with established bioavailability, which is crucial for the synthesis of hemoglobin and subsequent oxygen binding. The iron acts as a cofactor for numerous enzymes, including reductases and peroxidases, supporting essential iron-dependent enzyme functions. The prolonged-release mechanism controls the release kinetics of the iron source within the gastrointestinal tract, modulating the entry into the systemic circulation.

️ Cellular Energy and Systemic Cascade

Iron is a required component of the electron transport chain located in the mitochondria, necessary for the production of adenosine triphosphate (ATP) via oxidative phosphorylation. This core molecular function provides the metabolic foundation for high-demand cellular processes. The incorporation of iron into protoporphyrin is integral to the overall process of erythropoiesis (red blood cell production), representing the final systemic physiological cascade of the molecular activity.

How to Use Ферретаб комп.

The administration of Ферретаб комп. (Ferretab comp.) involves specific instructions to ensure the proper delivery and absorption of its active components, elemental iron and folic acid.

Administration Guidelines

Instruction	Guideline
Route of Administration	The product is designed exclusively for oral administration as a prolonged-release hard capsule.
Standard Dosing Pattern	The typical usage for prophylaxis and maintenance is one capsule once daily. For severe deficiency states, the dose may be increased to a regimen of one capsule two or three times daily.
Timing and Intake Conditions	For optimal absorption of iron, the capsule is generally recommended to be taken on an empty stomach. Administration should be separated by at least two hours from substances that inhibit iron absorption, such as antacids, dairy products, tea, or coffee.
Capsule Handling	The prolonged-release capsule must be swallowed whole with a full glass of water and must not be chewed, crushed, or sucked.

---

Use Duration and Age Context

Therapy duration is extended, requiring the course of treatment to continue for a minimum of four weeks after laboratory results confirm that the patient’s iron and hemoglobin levels have normalized. This long-term pattern is required to restore the body's iron reserves. The product is not recommended for use in children under 12 years of age. If a dose is missed, it is typically taken as soon as remembered; however, if it is close to the time for the next scheduled dose, the missed dose is skipped and the next dose is not doubled.

Research evidence / Overview of studies for Ферретаб комп.

Evidence for Combined Deficiency and Anemia Treatment

Research has explored the use of iron and folic acid combination products, such as Ферретаб комп., in the context of a combined deficiency of iron and folic acid, specifically anemia. The primary research involves Randomized Controlled Trials (RCTs), where patients receiving the combination product were compared to a placebo or an alternative treatment. These studies are often summarized in Systematic Reviews and Meta-analyses to describe overall patterns.

The studies primarily examined changes in important laboratory measures, particularly Hemoglobin (Hb) levels and Serum Ferritin (a measurement used to track iron stores). Research highlights changes measured during the study period in these parameters. The evidence provides context regarding how a lack of these two essential nutrients relates to outcomes related to systemic or functional imbalance.

---

Research in Pregnancy and Deficiency Prevention

A significant portion of the research has focused on the use of this combination during pregnancy, a time when the need for iron and folic acid is greatly increased. Studies have observed the medication both for treating documented deficiency in pregnant women and for prophylaxis—meaning the prevention of these deficiencies.

The research has explored short-term changes in pregnant women. Findings indicate that supplementation was associated with documented changes in blood markers. Furthermore, some trials examined the prevalence of maternal anemia at term (the time of delivery), and studies reported measurements of the incidence rate when compared to control groups.

---

Evidence Quality and Research Limitations

The evidence for iron and folic acid combination products is built on a foundation of numerous trials, which has contributed to a general scientific designation of Moderate evidence for this clinical context. Evidence quality varies across studies, and many clinical trials are subject to high variability (heterogeneity), meaning study conditions were not perfectly uniform. Long-term effects are not fully established, and certainty remains low for specific severe outcomes, such as severe anemia at term.

Key Studies & References

1. Ferrous Fumarate and Folic Acid tablets/capsules: NIH DailyMed Label
2. Maternal and child nutrition: NICE Guideline NG72 (Section on Micronutrient Supplements)

Common questions about Ферретаб комп. (FAQ)

Q: What exactly is Ferretab comp. prescribed for?

Official product information states that this preparation is typically used to prevent or treat conditions resulting from iron deficiency and iron deficiency anemia. Official guidance indicates use is typically determined by a physician based on a specific need for iron and folic acid supplementation.

Q: Is it true that Ferretab comp. can cause nausea or stomach upset?

Regulatory safety information describes nausea, constipation, diarrhea, and other forms of gastrointestinal discomfort as common occurrences. These effects are usually temporary, and discomfort is sometimes described as being potentially minimized when taken with food.

Q: What are the most common side effects of Ferretab comp.?

The most frequently documented side effects relate to the gastrointestinal system, including stomach upset, nausea, constipation, and diarrhea. This information is consistently noted in official regulatory documents for iron supplements.

Q: Is it normal for stool to become dark (black) after starting Ferretab comp.?

Regulatory documents confirm that it is common and considered normal for iron supplements to cause stools to turn a dark or black color. This is an expected outcome of taking the medication and is not generally associated with harm.

Q: Can Ferretab comp. cause an allergic reaction?

Regulatory information describes symptoms of a severe reaction, which, if observed, warrants prompt consultation with medical professionals. While rare, a serious allergic reaction is a possibility.

Q: How does Ferretab comp. interact with vitamins and other supplements?

Official information indicates that iron absorption can be affected by other mineral supplements, specifically those containing high levels of calcium, magnesium, or zinc. To optimize iron absorption, official information advises that the timing of these products should be separated, typically by several hours.

Q: Can Ferretab comp. be taken during pregnancy?

Official medical guidance often recommends iron supplements, including those combined with folic acid, when prescribed to treat or prevent low iron levels. The product is often used during this period when medically indicated, based on regulatory guidance for iron supplements.

Q: Is Ferretab comp. suitable for use while breastfeeding?

Official sources note that iron is a natural component of breast milk, and the product's use during this period is generally described as being unlikely to cause harm to the baby. Regulatory information suggests that taking iron supplements while breastfeeding is generally suitable.

Q: What are the contraindications for Ferretab comp.?

Official warnings highlight that iron therapy is typically contraindicated (not advised) for patients with conditions involving iron overload, such as hemochromatosis or certain types of anemia like hemolytic anemia. These conditions are listed as contraindications to prevent the risk of iron accumulation.

Q: Why are such strict contraindications listed in the official leaflet?

The primary reason for strict contraindications relates to the body's limited ability to excrete excess iron. Official sources explain that in individuals who already have conditions causing iron overload, supplementation could potentially lead to a risk of toxicity and organ damage.

Q: Should Ferretab comp. only be taken as prescribed by a doctor?

Regulatory documents emphasize that while some forms of iron may be available without a prescription, official guidance suggests that the management of confirmed deficiency or anemia should be overseen by a healthcare professional.

Q: How can Ferretab comp. help with chronic fatigue?

Iron is an essential component for the synthesis of hemoglobin, which is responsible for oxygen transport throughout the body. Because fatigue is a documented symptom of iron deficiency, addressing this deficiency is associated with an observed reduction in fatigue, a common symptom of low iron.

Q: Why is folic acid present in Ferretab comp.?

Folic acid (Vitamin B9) is included in the composition because it is required for proper red blood cell formation. It works in conjunction with iron to support the correction of anemia, and its presence is particularly relevant in patient groups like pregnant individuals.

Q: What happens if I accidentally take a double dose of Ferretab comp.?

Official warnings highlight that the accidental overdose of iron-containing products is a serious risk. Official warnings state that in cases of suspected overdose, prompt consultation with a healthcare professional or a national Poison Control Center is necessary.

Q: Can Ferretab comp. be taken by someone with liver diseases?

Official guidelines mention that iron is associated with risks of liver cirrhosis in cases of iron overload. Therefore, the official literature indicates that patients with significant liver conditions may require heightened caution and medical oversight.

Q: How can Ferretab comp. affect the condition of hair and nails?

Regulatory descriptions of iron deficiency symptoms include hair loss and brittle nails. Official sources indicate that when used to address the underlying deficiency, an improvement in the condition of the hair and nails is often observed over the course of treatment.

Q: Why is Ferretab comp. sometimes recommended to be taken with Vitamin C?

Official information states that Ascorbic acid, commonly known as Vitamin C, is often suggested alongside iron because it improves the absorption rate of the iron component in the stomach. This practice helps the body utilize the iron more effectively.

Q: Are there special instructions for storing Ferretab comp.?

Official guidelines specify that the product should be stored at controlled room temperature, typically between 15 C and 30 C. To maintain stability, it is also important to protect the capsules from excessive light and moisture.

Q: Can Ferretab comp. be taken in combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?

Official guidance notes that caution is typically warranted when combining iron supplements with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This is because NSAIDs carry a risk of gastrointestinal bleeding, which can lead to iron loss, potentially making the iron supplement less effective.

Q: Is there a risk of iron overdose when taking Ferretab comp.?

Yes, official safety warnings indicate that there is a risk of iron toxicity resulting from accidental overdose. Taking more than the recommended dosage carries a risk of iron toxicity and related adverse outcomes.

Q: Should I stop taking it if side effects appear?

Regulatory advice suggests that if common side effects persist or worsen, or if severe signs occur, a pharmacist or physician should be consulted promptly for evaluation.

Q: What is the reason for the restriction on alcohol consumption during treatment with Ferretab comp.?

Official health information suggests that both iron supplements and alcohol intake may individually cause gastrointestinal irritation. Therefore, combining them may increase the risk of experiencing stomach discomfort or nausea.

Q: In what cases might Ferre tab comp. be ineffective?

The effectiveness of the medication may be reduced if it is taken at the same time as substances known to inhibit iron absorption, such as antacids or supplements containing calcium. Furthermore, it is intended to address deficiencies specifically caused by a lack of iron, and not for treating other underlying causes of anemia.

How to Store and Dispose of Ферретаб комп. (Ferretab comp.)

Official regulatory documentation specifies mandatory conditions for the storage and disposal of this medicine, which contains ferrous fumarate and folic acid.

Storage Requirements

Storage Component	Requirement
Temperature Limit	Must be stored at a temperature not higher than 25 C.
Packaging	Must be kept in the original carton/packaging.
Stability	Do not use after the expiry date stated on the packaging.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Ферретаб комп. must not be disposed of via wastewater or household waste. Official instructions mandate consulting a pharmacist for proper disposal methods. Adhering to these rules is required to ensure environmental protection.